Telmisartan-based monotherapy and combination regimens for blood pressure control in adults with hypertension: a systematic review, meta-analysis, and GRADE assessment.
Baraah Abu Alsel, Muzun Saleh Alturqi Alanazi, Aryam Salem Mgairan Alrawaili et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of telmisartan-based antihypertensive regimens in adults with hypertension, analyzing 25 reports involving 6,521 participants. Telmisartan significantly reduced office systolic blood pressure by 6.39 mm Hg and diastolic blood pressure by 4.88 mm Hg, although the effects varied by comparator type. The certainty of evidence was low to moderate.
Key findings
- Telmisartan reduced office systolic blood pressure by 6.39 mm Hg (95% CI -7.86 to -4.93).
- Ambulatory systolic blood pressure decreased by 7.16 mm Hg (95% CI -10.61 to -3.72) based on two trials.
- Telmisartan improved blood pressure response (RR 1.68; 95% CI 1.31 to 2.16).
- Edema was less frequent with telmisartan therapy (RR 0.33; 95% CI 0.15 to 0.73).
Why it matters
Understanding the efficacy and safety of telmisartan-based regimens is crucial for clinicians managing hypertension, as these findings can inform treatment decisions and patient outcomes.
What to keep in mind
The study's findings are limited by low to moderate certainty of evidence, heterogeneity, and a predominance of trials conducted in Asian populations.